Health Care/Hospital

GC Biopharma Announces US FDA Approval for ALYGLO™ (Immune Globulin Intravenous, Human-stwk) 10% Liquid for Adults with Primary Humoral Immunodeficiency (PI)

YOGIN, South Korea, Dec. 17, 2023 /PRNewswire/ -- GC Biopharma Corp (006280.KS) today announces that the US Food and Drug Administration (FDA) has approved ALYGLO (immune globulin intravenous, human-stwk) 10% Liquid, formerly referred to as "GC5107," for the treatment of adult patients aged 17...

2023-12-18 09:49 1526

GeneQuantum and BioMap establish a strategic collaboration to jointly develop a series of next-generation ADC therapeutics

SUZHOU, China, Dec. 17, 2023 /PRNewswire/ -- Recently, GeneQuantum Healthcare (GQ), a global leader in ADC new drug development focused on innovative bioconjugation technologies, and BioMap, a global leader in life science AI Foundation protein-centric Large Language Models, announced that the...

2023-12-18 09:43 1365

First Patient Dosed in Clinical Trial of YOLT-201 for the Treatment of Hereditary ATTR-CM

SHANGHAI, Dec. 17, 2023 /PRNewswire/ -- YolTech Therapeutics today announced that the first patient has been dosed with YOLT-201, the company's firstin vivo genome editing candidate being developed as a single dose, potentially curative therapy for hereditary transthyretin amyloidosis with cardio...

2023-12-17 23:15 1578

Caliway Closes Oversubscribed Capital Raise and Secures Over $100M to Advance CBL-514 Pivotal Phase 3 Study in Subcutaneous Fat Reduction

TAIPEI, Dec. 16, 2023 /PRNewswire/ -- Caliway Biopharmaceuticals (Caliway) announced that it has closed an oversubscribed capital raise, securing over$100M by issuing 8 million new shares. The new funding will enable Caliway to advance the clinical development of its lead pipeline CBL-514, a sma...

2023-12-16 15:47 1984

Ubie Won the "Best with AI" in Google Play Best of 2023 (Japan)

NEW YORK, Dec. 15, 2023 /PRNewswire/ -- Ubie, Inc., headquartered at 1460 Broadway,New York, NY 10036 and led by CEO Kota Kubo, proudly announces that the Japanese version of Ubie's AI Symptom Checker (https://ubie.app/ ) has been awarded the "Best with AI" at the Google Play ...

2023-12-16 00:00 2236

SeekIn and OncoInv Collaborate to Expand the Global Accessibility of Multiple Cancer Detection Tests and Bridge Global Disparities in Cancer Care

SeekIn to Grant Oncolnv the Rights to Represent SeekIn's Comprehensive Range of Cancer Detection Tests in Twelve Countries to Provide Individuals with Accessible and Affordable Cancer Detection Tests SHENZHEN, China, Dec. 15, 2023 /PRNewswire/ -- SeekIn Inc, a leader in blood-based cancer early ...

2023-12-15 21:00 1499

Akeso Published Results from CD47 Antibody Ligufalimab in Combination with Azacitidine for Newly Diagnosed Higher-Risk Myelodysplastic Syndrome and Treatment-naïve Acute Myeloid Leukemia at ASH 2023

HONG KONG, Dec. 15, 2023 /PRNewswire/ -- Akeso published two phase Ib clinical results of its innovative CD47 monoclonal antibody ligufalimab (AK117) in combination with azacitidine in patients with newly diagnosed higher-risk myelodysplastic syndrome (HR-MDS) and treatment-naïve acute myeloid le...

2023-12-15 21:00 1631

Live from ASH 2023 | Oral Report Featuring Encouraging Data of Olverembatinib Combined with Reduced-Intensity Chemotherapy in Patients with Ph+ ALL Presented at the ASH Annual Meeting

SUZHOU, China and ROCKVILLE, Md., Dec. 14, 2023 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancer, chronic hepatitis B (CHB), and age-related diseases, announced today thatProf. Xiaoyuan Gong of the Institute of Hemato...

2023-12-15 11:14 1839

Nona Biosciences Enters into a Global License Agreement with Pfizer for HBM9033, an MSLN-Targeted Antibody-Drug Conjugate (ADC)

* Nona Biosciences will receive a total of up to $53 Million in upfront and near-term payments, with the potential for milestones of up to$1.05 billion plus royalties. * Pfizer partnership expands Nona's global network of collaborations, reinforcing its commitment to providing cutting-edge te...

2023-12-15 07:30 1672

Lunit to Acquire Volpara: Scheme Implementation Agreement Signed

- Lunit's strategic global leap: to acquire all of Volpara shares at AUD 1.15 per share, envisioning completion by Q2 2024 SEOUL. South Korea, Dec. 14, 2023 /PRNewswire/ -- Lunit (KRX:328130.KQ), a leading provider of AI-powered solutions for cancer diagnostics and therapeutics, today announced ...

2023-12-14 22:05 1489

China Jo-Jo Drugstores Granted A Second Extension to Meet Nasdaq Minimum Bid Price Requirement

HANGZHOU, China, Dec. 14, 2023 /PRNewswire/ -- China Jo-Jo Drugstores, Inc. (NASDAQ: CJJD) (the "Company"), a leading online and offline retailer and wholesale distributor of pharmaceutical and other healthcare products and healthcare provider inChina, today announced that on December 13, 2023, t...

2023-12-14 21:30 3509

Titans Gather, Future Embarks: The GenScript Biotech Global Forum coinciding with the 2024 J.P. Morgan Healthcare Conference in San Francisco to Convene 20+ KOLs, Exploring Disruptive Transformations and Infinite Opportunities in GCT

Keynote speaker Peter Marks to Deliver Address  Free Early Bird Registration Closing Soon NANJING, China, Dec. 14, 2023 /PRNewswire/ -- Technological advancements continuously empower the life sciences. Gene and cell therapy (GCT), as breakthrough treatments, are turning the once-unreachable dre...

2023-12-14 20:34 2421

Fosun Pharma's Global Multi-Center Phase III Clinical Trial Project for A New Antimalarial Drug Receives 500 Million Japanese Yen Investment from GHIT Fund to Jointly Improve the Global Accessibility of Antimalarial Drugs

SHANGHAI, Dec. 14, 2023 /PRNewswire/ -- The Japan-based Global Health Innovative Technology Fund (GHIT Fund) announced today that it will invest approximatelyUS$3.3 million (approximately 500 million yen[1]) in a global multicenter Phase III clinical trial project (the "Program") led by Fosun Ph...

2023-12-14 17:00 3820

Abbisko Therapeutics Announces that U.S. FDA Has Granted Fast Track Designation for Its CSF-1R Inhibitor Pimicotinib (ABSK021)

SHANGHAI, Dec. 13, 2023 /PRNewswire/ -- Abbisko Therapeutics Co., Ltd. ("Abbisko Therapeutics") today announced that its CSF-1R inhibitor pimicotinib (ABSK021) has been granted the fast track designation ("FTD") by the U.S. FDA for the treatment of tenosynovial giant cell tumor ("TGCT") patients ...

2023-12-14 08:30 1615

WAT Medical Joins World's Largest Boat Show

VANCOUVER, BC, Dec. 13, 2023 /PRNewswire/ -- Discover Boating Miami International Boat Show (DBMIBS) is the world's largest boat and yacht show. The convention, which attracts over 100,000 visitors from more than 35 countries, provides an opportunity for aquatic innovations and consumer products...

2023-12-13 22:00 1514

Virtual twin to improve treatment with cancer immunotherapies

COLOGNE, Germany, Dec. 13, 2023 /PRNewswire/ -- An international team started the research project CERTAINTY inDecember 2023. Together with partners from science, industry and the healthcare sector, the project team led by the Fraunhofer Institute for Cell Therapy and Immunology IZI aims to devel...

2023-12-13 21:06 1362

Alebund Reports Update for AP306 (EOS789), a First-in-Class Pan-inhibitor of Sodium-dependent Phosphate Transporters, from a Completed Phase II Clinical Trial in Patients with Hyperphosphatemia on Hemodialysis

SHANGHAI, Dec. 13, 2023 /PRNewswire/ -- Alebund Pharmaceuticals  ("Alebund" or the "Company"), an integrated biopharmaceutical company focusing on developing innovative therapies for the treatment of renal diseases and related chronic conditions, announcedphase II proof-...

2023-12-13 21:00 1582

Dizal's Sunvozertinib Pivotal Study Results Published in The Lancet Respiratory Medicine

SHANGHAI, Dec. 13, 2023 /PRNewswire/ -- Dizal today announced that the results of a phase 2 pivotal study of sunvozertinib for the treatment of platinum-pretreated non-small-cell lung cancer (NSCLC) patients with EGFR exon 20 insertion mutations (exon20ins) (WU-KONG6) were published in the peer-...

2023-12-13 18:00 1617

Live from ASH 2023 | Results from Chinese Studies of Olverembatinib Presented in Oral Report at the ASH Annual Meeting for the Sixth Consecutive Year, Including Data Showing Promising Efficacy in Patients with TKI-Resistant and/or Intolerant CML-CP

SUZHOU, China and ROCKVILLE, Md., Dec. 13, 2023 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancer, chronic hepatitis B (CHB), and age-related diseases, announced today that it has released updated data from a randomized...

2023-12-13 16:47 2373

WuXi Vaccines Wins Second Consecutive "Best Vaccine CMO Award" at AVEA 2023

SINGAPORE, Dec. 12, 2023  /PRNewswire/ -- WuXi Vaccines, a leading global vaccine Contract Development and Manufacturing Organization (CDMO), was named "Best Vaccine CMO of the Year" for the second consecutive year at the 2023 Asia-Pacific Vaccine Excellence Awards (AVEA) ceremony.  The AVEA 202...

2023-12-13 08:30 1485
1 ... 44454647484950 ... 269